[1] [2] According to the Wegovy SmPC, the medication works by mimicking the naturally occurring hormone GLP-1, which regulates appetite and food intake
Currently, once-weekly subcutaneous semaglutide 2.4 mg is approved for chronic weight management in adults with obesity, or overweight and with at least one weight-related comorbidity 17 , for reducing CV risk in adults with established cardiovascular disease (CVD) with obesity or overweight 18 , and in adolescents aged 12 years and older 19 , in conjunction with a reduced-calorie diet and increased physical activity plan
The evidence set still lacks a qualifying randomized or prospective test with a concurrent comparator and post-stop weight-regain endpoint for such an intervention
When to seek medical attention Seek immediate medical care for: Any signs of severe allergic reaction Fever with injection site infection signs Chest pain or significant cardiovascular symptoms Severe or persistent neurological symptoms Any symptom that feels like a medical emergency Seek prompt (but not emergency) medical attention for: Symptoms that persist beyond two weeks without improvement Symptoms that progressively worsen rather than improve New symptoms that appear after initial adjustment period Any symptom that significantly impairs daily function Do not let concern about discussing peptide use prevent you from seeking appropriate care
Without the need for reconstitution, it makes lab preparation for intranasal research easier
Tirzepatide prevents neurodegeneration through multiple molecular pathways